PERSON
FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis
Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment
Trump Nominates Renowned Surgeon Martin Makary as FDA Commissioner
Martin Makary, FDA Commissioner, Donald Trump, Johns Hopkins, Surgeon, Nomination
Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study
Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
UCB’s Bimzelx Receives FDA Approval for Moderate-to-Severe Hidradenitis Suppurativa, Marking Fifth Indication
Bimzelx, Bimekizumab, Hidradenitis Suppurativa, FDA Approval, IL-17A and IL-17F Inhibitor, Chronic Inflammatory Skin Disease
FDA’s Peter Marks Advocates for Open Dialogue on Vaccines Amid Controversy
FDA, Peter Marks, Vaccines, Open Dialogue, RFK Jr, HHS Nomination
Amgen Appoints Howard Chang as Senior Vice President of Research and Chief Scientific Officer
Howard Chang, Amgen, Chief Scientific Officer, Research, Biotechnology, Pharmaceutical Industry
Kyowa Kirin Invests $330M in Kura’s Leukemia Drug, Gaining Shared Rights Ahead of FDA Submission
Kyowa Kirin, Kura, leukemia drug, FDA submission, pharmaceutical investment
The Fallout of Research Misconduct: Implications for Neurodegenerative Disease Studies
Research misconduct, Neurodegenerative diseases, Eliezer Masliah, NIH investigations, Future of neurodegenerative research
Carolyn Bertozzi’s Valora Therapeutics Launches with $30M Seed Round to Develop Sugar-Based Immunotherapies
Carolyn Bertozzi, Valora Therapeutics, immunotherapy, sugar-based treatments, biotech startup, $30M seed round